Abstract |
Patients treated by aggressive cytostatic treatment exhibit marked deficiencies in cell-mediated immunity. Our investigations were performed in order to find out whether these immunosuppressive effects could be diminished by supportive treatment with the new synthetic immunomodulating compound BM 12.531, INN: AZIMEXONE. After inducing remission in ten patients with metastasizing breast cancer by a combination chemotherapy given for about one year, leucocytes, T- and B-lymphocytes and reactivity of peripheral lymphocytes to different mitogens were determined at weekly intervals before (8 X), during (8 X while on 100 mg i.v. weekly, then 4 X while on 400 mg i.v. weekly) and after (4 X) treatment with AZIMEXONE. Chemotherapy-induced immunosuppression could be markedly diminished during the administration of AZIMEXONE. A significant increase in the peripheral leucocyte count and mitogen-induced lymphocyte transformation could be achieved without any marked influence on the percentages of T- and B-cells. No severe side-effects of AZIMEXONE were observed.
|
Authors | R Kreienberg, D Boerner, F Melchert, E M Lemmel |
Journal | Journal of immunopharmacology
(J Immunopharmacol)
Vol. 5
Issue 1-2
Pg. 49-64
( 1983)
ISSN: 0163-0571 [Print] United States |
PMID | 6606686
(Publication Type: Journal Article)
|
Chemical References |
- Aziridines
- Azirines
- azimexon
|
Topics |
- Aziridines
(adverse effects, therapeutic use)
- Azirines
(therapeutic use)
- B-Lymphocytes
(immunology)
- Breast Neoplasms
(drug therapy)
- Cells, Cultured
- Female
- Humans
- Immunosuppression Therapy
- Leukocyte Count
- Lymphocyte Activation
(drug effects)
- T-Lymphocytes
(immunology)
|